An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults with X-Linked Hypophosphatemia (XLH)
Clinical Trial Grant
Administered By
School of Medicine
Awarded By
Ultragenyx Pharmaceutical
Start Date
November 1, 2015
End Date
April 30, 2017
Administered By
School of Medicine
Awarded By
Ultragenyx Pharmaceutical
Start Date
November 1, 2015
End Date
April 30, 2017